eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

Company Overview

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2 shs
• Average Volume: 2,826 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EFTR Stock Analysis - Frequently Asked Questions

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) posted its earnings results on Monday, November, 8th. The company reported $10.50 earnings per share for the quarter, beating analysts' consensus estimates of ($6.50) by $17.00. The company had revenue of $0.43 million for the quarter.

When did eFFECTOR Therapeutics' stock split?

eFFECTOR Therapeutics shares reverse split on the morning of Friday, January 12th 2024. The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of eFFECTOR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that eFFECTOR Therapeutics investors own include HubSpot (HUBS), Netflix (NFLX), Tesla (TSLA), Athenex (ATNX), ForgeRock (FORG) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 6/02/2025
• Next Earnings (Estimated): 7/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EFTR
• CIK: 1828522
• Web: www.locustwalkacquisitioncorp.com
• Phone: 858-925-8215
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.94) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,704,000
• Free Float: 4,483,000
• Market Cap: N/A
• Optionable: No Data
• Beta: 0.42